Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) inspected Unit-IV of APL Healthcare, a wholly owned subsidiary of the Company, situated at Palchur village and part of Palepalem Village Naidupeta Mandal, SPSR Nellore District, 524126, Andhra Pradesh, from 08 December to 17 December 2025.At the end of the current inspection, a �Form 483` was issued with 05 observations which are procedural in nature, and we will respond to the US FDA within the stipulated timelines. Powered by Capital Market - Live News

Aurobindo Pharma has received the Establishment Inspection Report (EIR) issued by the USFDA classifying Unit 1 of Apitoria Pharma, a wholly owned subsidiary of the company as `Voluntary Action Indicated (VAI)`. Powered by Capital Market - Live News

Net profit of Aurobindo Pharma rose 3.80% to Rs 848.45 crore in the quarter ended September 2025 as against Rs 817.38 crore during the previous quarter ended September 2024. Sales rose 7.73% to Rs 8236.96 crore in the quarter ended September 2025 as against Rs 7646.21 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales8236.967646.21 8 OPM %20.3720.48 - PBDT1705.111589.74 7 PBT1275.921207.46 6 NP848.45817.38 4 Powered by Capital Market - Live News

Aurobindo Pharma will hold a meeting of the Board of Directors of the Company on 5 November 2025.Powered by Capital Market - Live News

Aurobindo Pharma announced that S. Venkatesh Kumar, Associate Vice President, a Senior Management person of the Company vide his letter dated 03 July 2025 tendered his resignation and the Company has accepted his resignation and he has been relieved from his duties with effect from the close of business hours on 30 September 2025.Powered by Capital Market - Live News